Clinical trial
An International, Double-blind, Randomised, Placebo-controlled Phase IIb Trial to Assess the Efficacy, Safety, and Pharmacokinetics of GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis
NCT02782858 is registered in ClinicalTrials.gov with GeNeuro SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An International, Double-blind, Randomised, Placebo-controlled Phase IIb Trial to Assess the Efficacy, Safety, and Pharmacokinetics of GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis
- Lead sponsor
- GeNeuro SA
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2016
- Completion date
- December 31, 2017
- Enrollment
- 270 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.